<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-36 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-36</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-36</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-4.html">extraction-schema-4</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <p><strong>Paper ID:</strong> paper-8a7fb6d716f4c22351a8808b4fef0d094ddbaac5</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/8a7fb6d716f4c22351a8808b4fef0d094ddbaac5" target="_blank">Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</a></p>
                <p><strong>Paper Venue:</strong> Journal for ImmunoTherapy of Cancer</p>
                <p><strong>Paper TL;DR:</strong> This clinical practice guideline on immunotherapy for the treatment of melanoma, including rare subtypes of the disease (eg, uveal, mucosal), is developed with the goal of improving patient care by providing guidance to the oncology community.</p>
                <p><strong>Paper Abstract:</strong> Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, more recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long-term follow-up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence-free survival, and neoadjuvant strategies are an active area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma and bispecific T-cell engager therapy for HLA-A*02:01 genotype-positive uveal melanoma, are also available to patients. Despite the remarkable efficacy of these regimens for many patients with cutaneous melanoma, traditional immunotherapy biomarkers (ie, programmed death-ligand 1 expression, tumor mutational burden, T-cell infiltrate and/or microsatellite stability) have failed to reliably predict response. Furthermore, ICIs are associated with unique toxicity profiles, particularly for the highly active combination of anti-PD-1 plus anti-CTLA-4 agents. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of melanoma, including rare subtypes of the disease (eg, uveal, mucosal), with the goal of improving patient care by providing guidance to the oncology community. Drawing from published data and clinical experience, the Expert Panel developed evidence- and consensus-based recommendations for healthcare professionals using immunotherapy to treat melanoma, with topics including therapy selection in the advanced and perioperative settings, intratumoral immunotherapy, when to use immunotherapy for patients with BRAFV600-mutated disease, management of patients with brain metastases, evaluation of treatment response, special patient populations, patient education, quality of life, and survivorship, among others.</p>
                <p><strong>Cost:</strong> 0.031</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e36.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e36.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-716</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KEYNOTE-716</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase III randomized trial of adjuvant pembrolizumab versus placebo for completely resected stage IIB/IIC melanoma; protocol-specified anti-PD-1 exposure was up to 1 year and efficacy reported as RFS and DMFS benefit for pembrolizumab.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>KEYNOTE-716</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage IIB/IIC</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Adjuvant pembrolizumab for up to 1 year</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>recurrence events (RFS), distant metastasis-free survival (DMFS); not CR/PR in adjuvant context</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Pembrolizumab significantly prolonged RFS vs placebo (HR 0.65; 95% CI 0.46 to 0.92; p=0.00658). At second interim analysis HR for first recurrence or death 0.61 (95% CI 0.45 to 0.82). At 3rd interim analysis DMFS improved (HR 0.64; 95% CI 0.47 to 0.88). 12-month RFS 90.5% vs 83.1%.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade ≥3 treatment-related adverse events (TRAEs) 16.1% with pembrolizumab vs 4.3% with placebo</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e36.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate 76K</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CheckMate 76K (NCT04099251)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase III trial of adjuvant nivolumab versus placebo in completely resected stage IIB/IIC melanoma; nivolumab administered per-protocol for up to 1 year with a large reduction in recurrence risk reported.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>CheckMate 76K</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage IIB/IIC</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Adjuvant nivolumab for up to 1 year (480 mg every 4 weeks reported in table)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>recurrence events (RFS), stage-specific 12-month RFS, DMFS</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Adjuvant nivolumab reduced risk of recurrence or death (HR 0.42; 95% CI 0.30 to 0.59; p<0.0001). Overall 12-month RFS 89.0% vs 79.4% (nivolumab vs placebo). Stage-specific 12-month RFS reported (eg, IIB 93% vs 84%; IIC 84% vs 72%).</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade 3-4 TRAEs 10.3% with nivolumab vs 2.3% with placebo</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e36.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate 238</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CheckMate 238 (NCT02388906)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Double-blind phase III adjuvant trial comparing nivolumab versus ipilimumab in resected stage IIIB/IIIC or resected stage IV melanoma; nivolumab given every 2 weeks for up to 1 year with superior RFS and lower toxicity vs ipilimumab.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>CheckMate 238</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage IIIB/IIIC and resected stage IV</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Nivolumab 3 mg/kg every 2 weeks for up to 1 year</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>recurrence-free survival (RFS) and overall survival (OS); comparison to ipilimumab arm</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>12-month RFS 70.5% (nivolumab) vs 60.8% (ipilimumab); HR 0.65 (97.56% CI 0.51 to 0.83; p<0.001). 4-year RFS 51.7% vs 41.2% (HR 0.71). OS differences were small and study underpowered for OS (4-year OS 77.9% vs 76.6%).</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td>Study noted more patients in ipilimumab arm received subsequent immunotherapy; no explicit data presented on relapse after stopping nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade ≥3 TRAEs 14.4% with nivolumab vs 45.9% with ipilimumab; treatment discontinuation due to AE 9.7% (nivolumab) vs 42.6% (ipilimumab).</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td>9.7% discontinued nivolumab due to adverse events; higher discontinuation in ipilimumab arm largely due to toxicity</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e36.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-054</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EORTC1325/KEYNOTE-054</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Double-blind phase III adjuvant trial of pembrolizumab versus placebo for resected stage III melanoma; pembrolizumab administered for up to 1 year with significant RFS and DMFS benefits.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>EORTC1325/KEYNOTE-054</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage IIIA (>1 mm LN metastasis), IIIB, IIIC</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Adjuvant pembrolizumab for up to 1 year</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>recurrence-free survival (RFS), distant metastasis-free survival (DMFS)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>1-year RFS 75.4% (pembrolizumab) vs 61.0% (placebo); HR 0.57 (98.4% CI 0.43 to 0.74; p<0.001). 3.5-year DMFS 65.3% vs 49.4% (HR 0.60).</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade ≥3 TRAEs 14.7% with pembrolizumab vs 3.4% with placebo; irAEs of any grade 37.3% vs 9.0%.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e36.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-006</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KEYNOTE-006</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase III trial of pembrolizumab (two dosing schedules) versus ipilimumab for unresectable/metastatic melanoma; pembrolizumab showed superior PFS and OS with many patients receiving prolonged therapy including 19% completing 2 years.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>KEYNOTE-006</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>unresectable/metastatic (first-line or ≤1 prior therapy allowed)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Pembrolizumab 10 mg/kg every 2 weeks or every 3 weeks; treatment continued per protocol with many patients treated long-term (some completed 2 years)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td>6.0 months</td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>ORR (CR, PR), PFS, OS</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>ORR 32.9% (pembrolizumab) vs 11.9% (ipilimumab); median PFS favored pembrolizumab (median ~8.4 months vs 3.4 months; HR 0.57). Median OS 32.7 months (pembrolizumab) vs 15.9 months (ipilimumab). 19% of pembrolizumab patients completed 2 years of treatment.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>CR rate 6.1% in pembrolizumab arm (other categories PR/SD reported as part of ORR and DCR)</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td>Exploratory rechallenge data: 13 patients received a second course of pembrolizumab; outcomes included 3 CRs, 4 PRs, 3 SDs, 1 PD, 2 pending (reported in guideline).</td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade ≥3 TRAEs ~10.1% for pembrolizumab groups vs 19.9% for ipilimumab group in this trial</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e36.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate 067</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CheckMate 067 (NCT01844505)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase III trial comparing nivolumab, ipilimumab, and the combination for treatment-naïve unresectable/metastatic melanoma; combination delivers higher ORR and longer PFS/OS with substantial grade 3-4 toxicity; maintenance nivolumab continued after induction.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>CheckMate 067</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (alone and in combination with ipilimumab)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>unresectable/metastatic first-line</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Induction with ipilimumab plus nivolumab followed by nivolumab maintenance (typically until progression or unacceptable toxicity); no fixed short-duration stopping rule reported in excerpt</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>ORR (CR, PR), PFS, OS</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Median PFS 11.5 months (combination) vs 6.9 months (nivolumab) vs 2.9 months (ipilimumab). With minimum follow-up 6.5 years, median OS 72.1 months (combination) vs 36.9 months (nivolumab) vs 19.9 months (ipilimumab). ORR 57.6% (combination) with CR 11.5%.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>CR rates reported (11.5% combo; 8.9% nivolumab), but no duration-stratified efficacy by CR/PR in excerpt</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade 3-4 TRAEs 55.0% (combination) vs 16.3% (nivolumab); 36.4% of combination arm discontinued study drug due to TRAE.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td>36.4% discontinued combination therapy due to TRAEs (toxicity-driven discontinuation emphasized)</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e36.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>IMMUNED</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>IMMUNED (phase II)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase II double-blind trial in resected stage IV (NED) melanoma comparing adjuvant nivolumab plus ipilimumab, nivolumab monotherapy, and placebo; reported RFS benefit for combination and distinct toxicity profiles.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>IMMUNED</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (alone and combined with ipilimumab)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant resected stage IV (NED)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Nivolumab regimens administered per trial (eg, nivolumab 3 mg/kg every 2 weeks arm; combination used nivolumab and ipilimumab induction schedules); explicit total planned duration not stated in excerpt</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>1-year and 2-year RFS rates, OS</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>1-year and 2-year RFS: combination arm 75% and 70%, nivolumab arm 52% and 42%, placebo 32% and 14%; combination vs placebo OS HR 0.41 (95% CI 0.17 to 0.99).</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade 3-4 TRAEs 71% (ipilimumab plus nivolumab) vs 27% (nivolumab); three deaths due to adverse events reported (unrelated to study drug).</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e36.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized phase II trial comparing neoadjuvant pembrolizumab (three doses) continued into adjuvant treatment versus upfront surgery followed by adjuvant pembrolizumab in resectable stage IIIB–IV melanoma; endpoint EFS favored the neoadjuvant-adjuvant sequence.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant + adjuvant for resectable stage IIIB–IV</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Three doses neoadjuvant pembrolizumab continued into adjuvant versus upfront surgery followed by adjuvant pembrolizumab (total planned systemic exposure per protocol; specific total duration not enumerated in excerpt)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Event-free survival (EFS), resection rates, adverse events</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Neoadjuvant-adjuvant arm showed significantly improved EFS versus adjuvant-only arm (p=0.004) after median follow-up 14.7 months.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Similar rates of pembrolizumab-related vs surgery-related adverse events reported between arms</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Neoadjuvant followed by adjuvant pembrolizumab improved EFS compared with adjuvant alone in this trial, but guideline does not prescribe a generalized stopping-duration rule.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e36.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NADINA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NADINA (randomized phase III)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized phase III comparing neoadjuvant ipilimumab plus nivolumab followed by surgery with response-driven adjuvant therapy versus surgery followed by 12 cycles of adjuvant nivolumab for resectable macroscopic stage III melanoma; the neoadjuvant/response-driven strategy improved EFS but had higher toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>NADINA (NCT04949113)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (in combination with ipilimumab neoadjuvantly; adjuvant nivolumab in comparator arm)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant for resectable macroscopic stage III (perioperative)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Neoadjuvant ipilimumab + nivolumab followed by surgery with response-driven adjuvant therapy (only partial/non-responders received adjuvant) versus surgery followed by 12 cycles of adjuvant nivolumab (fixed-duration adjuvant ~12 cycles)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Major pathological response (MPR), 12‑month event-free survival (EFS), safety</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td>Neoadjuvant arm: adjuvant therapy given only to partial responders or non-responders; patients with major/pathologic complete responses often spared adjuvant therapy</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Neoadjuvant/response-driven arm: MPR 59%; estimated 12-month EFS 83.7% (99.9% CI 73.8% to 94.8%). Adjuvant-only arm: estimated 12-month EFS 57.2% (99.9% CI 45.1% to 72.7%).</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>MPR rate 59% in neoadjuvant group; better 12-month EFS observed in neoadjuvant group, indicating response-adapted strategy associated with superior short-term EFS.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade ≥3 systemic AEs related to systemic therapy: 29.7% (neoadjuvant group) vs 14.7% (adjuvant group). Endocrinopathies more frequent with neoadjuvant (30.7% vs 9.9%).</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Neoadjuvant ipilimumab plus nivolumab with response-driven adjuvant therapy produced longer EFS than fixed-duration (12-cycle) adjuvant nivolumab, but at the cost of higher toxicity; guideline highlights benefit but notes increased adverse events.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e36.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo / PRADO</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN-neo (and PRADO extension)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase II neoadjuvant study testing different ipilimumab + nivolumab dosing regimens and a PRADO extension using index-node pathologic response to adapt surgery and adjuvant therapy; demonstrated that response-adapted de-escalation (omitting TLND/adjuvant for MPR patients) yielded high 2-year RFS.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>OpACIN-neo / PRADO</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (combined with ipilimumab in neoadjuvant regimens)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant for macroscopic stage III</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Neoadjuvant regimens of two cycles of combination ipilimumab + nivolumab with differing dose permutations (eg, ipi1+nivo3 vs ipi3+nivo1) with subsequent surgery; adjuvant therapy and extent of surgery adapted based on index nodal pathologic response</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Pathologic response (pCR, major pathologic response MPR ≤10% viable tumor), radiographic response, 2-year RFS and DMFS</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td>Patients with index node MPR proceeded without therapeutic lymph node dissection (TLND) and many avoided adjuvant systemic therapy (response-driven omission of surgery/adjuvant)</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>In PRADO, patients with index LN MPR (n=60) who omitted TLND had 2-year RFS 93.3% and DMFS 100%; flipped-dose neoadjuvant (ipi1+nivo3) produced lower grade ≥3 irAEs (20% vs 40%) with similar pathologic response rates.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>MPR subgroup: 2-year RFS 93.3% and DMFS 100%; patients without pathologic response had lower RFS (eg, 2-year RFS reported 55% for no pathologic response in separate neoadjuvant study with relatlimab+nivolumab).</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td>Omission of TLND and adjuvant therapy in MPR patients was associated with durable RFS within the follow-up window reported (no increase in early distant metastasis in MPR cohort).</td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Flipped-dose regimen (ipi1+nivo3) had lower grade ≥3 irAEs (20%) compared with standard (ipi3+nivo1) (40%) while maintaining similar response rates.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Response-adapted perioperative strategies (pathology-driven omission of surgery and adjuvant therapy for MPR patients) produced high short-term RFS/DMFS and reduced surgical morbidity; considered promising but not definitive standard at time of guideline.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>KEYNOTE-716 <em>(Rating: 2)</em></li>
                <li>CheckMate 76K <em>(Rating: 2)</em></li>
                <li>CheckMate 238 <em>(Rating: 2)</em></li>
                <li>EORTC1325/KEYNOTE-054 <em>(Rating: 2)</em></li>
                <li>KEYNOTE-006 <em>(Rating: 2)</em></li>
                <li>CheckMate 067 <em>(Rating: 2)</em></li>
                <li>IMMUNED <em>(Rating: 1)</em></li>
                <li>SWOG S1801 <em>(Rating: 2)</em></li>
                <li>NADINA <em>(Rating: 2)</em></li>
                <li>OpACIN-neo / PRADO <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>